Donaldson acquires Univercells Technologies

Donaldson acquired Univercells Technologies, a global producer of biomanufacturing solutions for cell and gene therapy research, development and commercial manufacturing. Univercells Technologies’ product offering includes the unique scale-X single-use structured fixed-bed bioreactor for the intensified production of viruses used in cell and gene therapy, viral vaccines and other therapeutics. In addition, the company’s automated NevoLine Upstream platform incorporates industry-standard filtration to provide integrated up- and mid-stream processing capabilities in a single unit. Headquartered in Nivelles, Belgium, Univercells Technologies has over 100 employees globally. The Company generated approximately EUR10M of revenue in calendar 2022 and was acquired for cash consideration of EUR136M on a cash-free, debt-free basis and subject to closing adjustments. Univercells Technologies is being acquired from Gamma Biosciences and Univercells SA and will be a part of the Donaldson Life Sciences segment. Baker McKenzie acted as legal advisors to Donaldson.